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Abstract  
The Hippo pathway is a conserved pathway that interconnects with several other 
pathways to regulate organ growth, tissue homeostasis and regeneration, and stem cell 
self-renewal. This pathway is unique in its capacity to orchestrate the multiple processes, 
from sensing to execution, necessary for organ expansion. Activation of the Hippo 
pathway core kinase cassette leads to cytoplasmic sequestration of the nuclear effectors 
YAP and TAZ, consequently disabling their transcriptional coactivation function. 
Components upstream of the core kinase cassette have not been well understood, 
especially in vertebrates, but are gradually being elucidated and include cell polarity and 
cell adhesion proteins. Like many signalling proteins, Hippo pathway proteins are 
modular and utilise various interaction and catalytic domains to transmit signals and 
regulate transcription of target genes, often in a context-dependent fashion. In this review 
we outline the major protein components and focus on the structure and function of some 
of the key Hippo pathway domains in vertebrates. 
 
Introduction to the Hippo pathway and its role in organ growth control 
The Hippo pathway has emerged over the last decade as a key player in organ size 
regulation during development, tissue homeostasis throughout adult life, tissue 
regeneration and stem cell self-renewal [1-8].  Perhaps unsurprisingly, the pathway also 
plays a role in tumour suppression. Hippo pathway components were first identified 
through loss of function genetic screens in Drosophila melanogaster; the Hpo gene, after 
which the pathway has been called, was named for the mutant overgrown head phenotype 
that resembled hippopotamus hide [9]. 
 
Hippo pathway components 
The core elements of the Hippo pathway are well known but additional components 
constituting an extended network continue to be identified. Core components of the 
vertebrate pathway (Fig. 1) include the MST1/2 kinases, each of which 
autophosphorylates its activation loop then phosphorylates and forms an active complex 
with Sav1. MST1/2 can then phosphorylate the LATS1/2 kinases and their co-activator 
MOB1. LATS1 or LATS2 subsequently phosphorylates the most downstream targets of 
the Hippo pathway, YAP and TAZ, enabling 14-3-3 proteins to bind and sequester 
YAP/TAZ in the cytoplasm (Fig. 1). The Hippo pathway is less complex in Drosophila 
than in vertebrates; where two orthologues exist in vertebrates, for example, only one 
exists in Drosophila. The core components in Drosophila, with vertebrate homologues in 
parentheses, are Hippo (MST1/2), Sav (Sav1), Warts (LATS1/2), MATS (MOB1) and 
Yorkie (YAP/TAZ). 
 
When the Hippo pathway is inactivated, YAP and TAZ translocate to the nucleus where 
they behave as co-activators for various transcription factors. YAP and TAZ lack a DNA 
binding domain and so influence transcription by interacting with DNA binding proteins. 
Organ growth is promoted by the interaction of YAP and TAZ with TEAD family 
transcription factors which upregulate transcription of genes that promote cell 
proliferation, survival, differentiation and morphogenesis [10]. TEAD transcription 
factors are ubiquitously expressed, though each TEAD protein (TEAD1-TEAD4) 
occupies a slightly different niche with respect to tissue expression and developmental 
stage.  
 
Knowledge of upstream signals that regulate organ size and morphology is key to 
understanding and modulating the Hippo pathway. Recent studies have highlighted the 
influence of cell contacts on regulation of Hippo and associated pathways. The Crumbs 
(Crb) complex, which is associated with tight junctions in the sub-apical region of the 
cell membrane, regulates the Hippo pathway in Drosophila through interactions with the 
upstream Hippo regulator Expanded (Ex) [11]. It is unclear whether the Crb-Ex 
mechanism is conserved in mammals but, in response to high cell density, Crb can 
directly inhibit nuclear translocation of YAP (Fig. 1), in addition to contributing to Hippo 
pathway activation through an unidentified mechanism [12]. E-cadherin, a trans-
membrane protein that forms the intercellular epithelial junction complex, was recently 
found to be an upstream regulator of the Hippo pathway. E-cadherin induces cell contact 
inhibition, a phenomenon that stops cellular proliferation upon confluence. E-cadherin 
recruits to the cell membrane; β-catenin then activates the Hippo pathway through 
interactions with Merlin/NF2 [13]. 
 
Organ growth control and tumourigenesis 
Hippo signalling orchestrates organ growth through its coordination of cell proliferation, 
survival, differentiation and polarity. Numerous examples have illustrated that 
deregulation of the pathway leads to significantly increased organ size. Upregulation of 
YAP, the target protein that is inhibited by the Hippo pathway, increased mouse liver size 
from around 5% of body weight to around 25% in four weeks [14]. Similarly, when core 
Hippo pathway proteins MST1/2 and Sav1 were knocked out in mouse livers, the organs 
were significantly larger than those of wild-type mice [15-18]. An enlarged heart 
phenotype has also been observed in Sav1 knockout mice [19]. In all cases, organ 
structure was preserved, as observed previously for Drosophila Hippo pathway mutants 
which also display enlarged organs (heads, imaginal discs) with normal tissue patterns 
[20]. 
 
Constitutive YAP over-expression or liver-specific deletion of MST1/2 or Sav1 induces 
multi-focal tumourigenesis, highlighting the role of the pathway in tumour suppression 
[14, 16-18]. YAP and TAZ can induce anchorage-independent growth and epithelial-
mesenchymal transition (EMT) of immortalised mammary and pancreatic epithelial cells 
[12]. EMT is important in normal morphological processes but when deregulated in 
cancers is involved in metastasis, tumour recurrence and therapeutic resistance. Upstream 
Hippo pathway components function as tumour suppressors. Hippo pathway mutations 
have been observed in a range of human cancers including breast cancers, soft tissue 
sarcomas, melanomas, colorectal cancers, ovarian carcinomas, retinoblastomas, 
astrocytomas, and neurofibromatosis type 2 [1, 5]. There has been speculation about the 
possible involvement of Hippo signalling in cancer stem cells due to the pathway’s links 
to stem cell self-renewal and cancer; recently the Hippo pathway, via TAZ, was 
identified as a molecular link between EMT, cell polarity and cancer stem cells in breast 
cancer [21].  
 
Integration of multi-pathway signalling  
The Hippo pathway interacts with numerous other signalling pathways (Table 1), some of 
which contribute to organ growth regulation. This cross-talk occurs in both cytoplasm 
and nucleus and is probably important for the tight control of cell proliferation, growth, 
polarity and differentiation required for formation and maintenance of functional 
proportionate organs without crossing the boundary into tumourigenesis. Some of the 
inter-connections with the Hippo pathway are described below [2, 7, 8, 22]. 
 
Canonical Wnt pathway 
Wnt signalling activates membrane-bound Dishevelled (Dvl) which inhibits the 
axin/GSK-3/APC β-catenin destruction complex (β-catenin is the nuclear effector of Wnt 
signalling). When membrane-localised β-catenin dissociates from E-cadherin and α-
catenin, it translocates to the nucleus where it interacts with Lef/Tcf transcription factors, 
causing the activation of target genes that determine stem cell survival and 
differentiation. The Hippo pathway inhibits the canonical Wnt pathway by enhancing 
levels of cytoplasmic phosphorylated TAZ, which binds to Dvl [23]. This interaction 
prevents Dvl phosphorylation, rendering Dvl inactive. In the absence of hyper-
phosphorylated Dvl, β-catenin does not reach the nucleus and is targeted for degradation. 
The links between Hippo and Wnt signalling are not limited to the cytoplasmic TAZ-Dvl 
interaction; the E-cadherin/β-catenin/α-catenin complex binds Merlin and activates the 
Hippo pathway [13]. Also, upon Hippo pathway abrogation, nuclear non-phosphorylated 
TEAD-bound YAP forms a complex with Lef/Tcf-bound β-catenin. YAP-β-catenin 
complex formation leads to up-regulation of Sox2 and Snai2 genes and consequent 
increase in heart size [19].  
 
TGFβ  and BMP signalling 
The Hippo pathway has multiple connections with TGFβ and BMP signalling. Upon 
 TGFβ or BMP interaction with their respective membrane-bound receptors, cytoplasmic 
Smad proteins are activated by phosphorylation in the C-terminal region. Smad proteins 
contain an N-terminal MH1 domain that binds DNA and a C-terminal MH2 protein-
protein interaction domain. Upon activation, Smads translocate to the nucleus where they 
form transcription factor complexes. When nuclear Smad2/3 forms a complex with 
nuclear YAP/TAZ, Smad2/3 is prevented from returning to the cytoplasm and genes that 
promote EMT are upregulated [12]. Phosphorylation of the Smad inter-MH domain 
linker by cyclin dependent kinase (CDK) 8/9 promotes Smad-YAP/TAZ interaction 
which upregulates transcription of target genes when the proteins are nuclear [24]. The 
Hippo pathway can therefore inhibit TGFβ and BMP signalling by inducing cytoplasmic 
retention of YAP/TAZ, consequently sequestering YAP/TAZ-bound Smad2/3 or 
Smad1/5/8 proteins to the cytoplasm.  
 
Mechanotransduction 
An increase in extracellular matrix (ECM) rigidity, such as in bone, causes Rho GTPase 
activation and leads to stress fibre formation. When cytoskeletal tension increases in 
response to stiff ECM, YAP and TAZ are retained within the nucleus and mesenchymal 
stem cells (MSCs) differentiate into osteoblasts. Conversely, when the MSCs are grown 
on soft ECM with low intracellular cytoskeletal tension, YAP and TAZ are excluded 
from the nucleus, and the cells can differentiate into other lineages such as adipocytes. 
The Hippo pathway regulator E-cadherin can control Rho activation, but in this case E-
cadherin may not be involved as mechanotransduction-mediated control of YAP/TAZ 
cellular localisation occurs independently of the core Hippo pathway [25].  
 
Pro-apoptotic and other interactions 
In addition to TEADs and Smads, YAP and TAZ interact with other transcription factors, 
for example PPARγ and p73, which can result in repressed transcription or pro-apoptotic 
effects. YAP and TAZ interact with a host of other proteins (Table 2), in some cases 
without any apparent connection to the canonical Hippo pathway. As YAP and TAZ are 
the most downstream targets of the pathway, elucidating the function of these YAP/TAZ 
complexes is vital for understanding the control of organogenesis and tissue homeostasis. 
 
Key Hippo pathway domains 
Regulation of organ growth, tissue homeostasis, tissue regeneration and stem cell self-
renewal by Hippo pathway components depends on protein-protein, protein-nucleic acid 
and protein-membrane interactions and in some instances multi-protein complex 
formation. The binding properties of a range of domains or motifs within Hippo pathway 
proteins promote these interactions. Hippo pathway proteins generally contain multiple 
domains or motifs separated by various lengths of often unstructured polypeptide (Fig. 2). 
 
TEAD-YAP/TAZ interaction domains 
The major nuclear proteins regulated by the Hippo pathway are the TEAD transcription 
factors (Fig. 1). TEAD proteins comprise an N-terminal DNA-binding domain (DBD) 
and a C-terminal YAP-binding domain (YBD), both of which are indispensable because 
individually YAP and TEAD have no transcriptional activity. The TEAD DBD can bind 
to a variety of M-CAT-like DNA sequences (the M-CAT motif is 5′-TCATTCCT-3′) in a 
fairly promiscuous manner. The solution structure of human TEAD1 (TEF-1) A49S 
mutant DBD comprises a three-helix bundle in a homeodomain-like fold. The first two α-
helices are almost anti-parallel with the third α-helix lying across them (Fig. 3). Similar 
to homeodomain proteins, DNA binding is mediated by the third α-helix (H3) and the 
preceding loop (L2); H1 and L1 do not bind directly but are necessary for full strength 
binding of TEAD to tandem M-CAT sites [26]. 
 
The TEAD-binding domain (TBD) of YAP/TAZ, located in the N-terminal region, is 
natively unstructured and binds TEAD with high fidelity - to date no other protein 
interactions are known to involve the TBD. The crystal structures of YAP-TEAD 
interaction domains involving human TEAD2 [27], human TEAD1-YAP [28] and mouse 
TEAD4-YAP [29] show that the TEAD YBDs adopt an immunoglobulin-like β-sandwich 
fold with the addition of two helix-turn-helix motifs (Fig. 3). The Y421H mutation in 
TEAD1 that is present in human Sveinsson’s chorioretinal atrophy was previously found 
to abrogate interactions with YAP and TAZ [30]. Consistent with this, Y421 is located in 
the TEAD-YAP interface where it forms a hydrogen bond with a Ser residue in YAP 
(S94 in human YAP). Upon interaction with TEAD, YAP TBD forms two α-helices that 
pack into binding grooves and are separated by an extended loop that wraps around the 
YBD [28, 29]. 
 
YAP/TAZ transcription activation domain (TAD) 
Both YAP and TAZ contain a C-terminal TAD [31]. Although there have been no 
experimental studies of the structure of this domain, secondary structure predictions 
indicate that it is largely unstructured.  
 
YAP/TAZ cytoplasmic sequestration by 14-3-3 
C-terminal to the YAP/TAZ TBD is an HxRxxS motif that becomes a 14-3-3 binding site 
upon Ser phosphorylation (S127 in human YAP). A crystal structure of the homodimeric 
14-3-3σ:YAP phospho-peptide complex (Fig. 3) reveals that the YAP peptide binds to 
each monomer of 14-3-3σ with 1:1 stoichiometry, so each 14-3-3 dimer can bind two 
molecules of YAP [32]. 14-3-3σ dimerises in a W-shape via α-helices 1-4. Helices 3, 5, 
7, and 9 on each monomer form the YAP-binding groove. The YAP peptide-bound 14-3-
3σ structure is very similar to unbound 14-3-3σ with an overall r.m.s.d. (root mean 
square deviation) between the structures of of 1.00 Å, suggesting that YAP binding does 
not induce a large conformational change in 14-3-3. 
 
WW domains 
WW domains are prevalent and important features of the Hippo pathway: YAP, TAZ, 
Sav1, Kibra and Itch each contain at least one WW domain [33]. The WW domain 
(approximately 40 residues) is the smallest known protein domain and consists of a 
twisted three-stranded β-sheet (Fig. 3). WW domains are named after two signature Trp 
residues located on the first and third β-strands. The first Trp is required for folding and 
the second Trp is involved in ligand binding [34]. WW domains are central mediators of 
protein binding events throughout the extended Hippo network via interactions with 
proline-rich motifs. WW domains are categorised into five groups (I-V) according to 
their cognate ligand. The main Hippo pathway WW domains fall into group I i.e. the 
WW domains bind to PY motifs (PPxY and, less frequently, LPxY) such motifs are 
found, for example, in LATS1/2, most of the Smads, Dvl, and p73.  
 
Itch contains four WW domains and inhibits the Hippo pathway by binding to PPxY 
motifs of LATS1/2, predominantly via its first WW domain, leading to ubiquitination and 
degradation of LATS1/2 [35]. Sav1 and Kibra both contain two WW domains; in each 
case, WW1 is a group I domain, and WW2 is atypical in that the second Trp is replaced 
by another amino acid (I in Kibra, Y in vertebrate Sav1 and R in Drosophila Sav). Mouse 
Sav1 WW2 is the only WW domain known to date to dimerise (Fig. 3) [36]. Sav1 
promotes multi-protein complex formation in the Hippo pathway by acting as a scaffold 
protein through SARAH domain multimerisation. It is possible that WW2 
homodimerisation enhances this scaffolding function whilst WW1 engages binding 
partners.  
 
The YAP1 and YAP2 isoforms of YAP contain one and two WW domains respectively. 
It is not currently clear what specific roles the different isoforms play. YAP and TAZ 
have around 20 known binding partners (Table 2) many of which bind via at least one of 
the WW domains; given the prevalence of PPxY motifs in proteomes, the number of 
protein-protein interactions mediated by YAP and TAZ could be much higher than this. 
The WW domains of YAP and TAZ belong to group I [37], but YAP WW1 has also been 
found to interact with a phospho-serine motif of Smad1 [24]: phosphorylation by 
CDK8/9 (as part of BMP signalling) creates a YAP WW1 binding site on the Smad1 
inter-MH domain linker (see “TGFβ  and BMP signalling” above). This region also 
contains a PPxY motif that binds to YAP WW2. CDK8/9 phosphorylation also primes 
Smad1 for phosphorylation by GSK3. Secondary phosphorylation of Smad1 by GSK3 
reduces the affinity for YAP WW1 and increases the affinity for Smurf1 WW1; Smurf1 
WW2 simultaneously binds the PPxY motif. Interactions with Smurf1 lead to poly-
ubiquitination and subsequent proteasomal degradation of Smad1, thereby marking the 
end of a YAP-Smad transcriptional event. Wnt signalling suppresses GSK3, providing 
another illustration of the complexity of inter-pathway connections. 
 
SARAH domains 
The SARAH coiled coil domain is present in the C-terminal region of Sav1, Rassf and 
Hippo (MST1/2). SARAH domains homodimerise and can also mediate 
heterodimerisation of Hippo pathway proteins, for example between MST1/2 and Sav1. 
The solution structure of human MST1 SARAH homodimer (Fig. 3) shows that each 
monomer comprises a short N-terminal α-helix that is oriented towards the N-terminal 
helix of the other monomer, and an elongated C-terminal α-helix along which the anti-
parallel dimer interface lies [38]. The Rassf5 (Nore1) SARAH domain forms a 
homotetramer but in the presence of MST1 SARAH domain only dimers are observed. 
The role of mammalian Rassf proteins in the Hippo pathway is currently unclear; in vitro 
studies indicate that Rassf1 and Rassf5 inhibit the Hippo pathway, as is the case for 
Drosophila Rassf. Conversely, in some cases the Hippo pathway seems to be activated by 
Rassf proteins in vivo [1].  
 
Ser/Thr kinase domains 
Central to the Hippo pathway are the Ser/Thr kinase domains of MST1/2 and LATS1/2 
that propagate phosphorylation events to retain YAP/TAZ in the cytoplasm. MST1/2 
belong to the Ste group of kinases, whereas LATS kinases are similar to the PKC family. 
In a crystal structure of activated MST1 (Fig. 3), the auto-activation loop is di-
phosphorylated. There are currently no published structures of the LATS1 and LATS2 
kinase domains.  
 
MOB1 
MOB1 is part of the Mps One binder (MOB) family of co-activator proteins [39]. Human 
MOB1 binding to LATS1/2 triggers LATS1/2 auto-phosphorylation on the activation 
segment. The MOB1-LATS1/2 complex phosphorylates YAP/TAZ. The C-terminal core 
domain adopts an α-helical fold common to all MOB proteins whereas the N-terminal 
region is less conserved but seems to be functionally important. In S. cerevisiae MOB1, 
this N-terminal region includes structural elements that mediate homodimerisation in 
vitro [40]. One side of the MOB1 surface is mostly acidic and the opposite side is basic. 
Bioinformatic and experimental analyses indicate that the interaction between MOB1 and 
LATS1/2 is mediated by the acidic face of the former and the basic region of the N-
terminal regulatory domain of the latter. 
 
PDZ binding motifs 
YAP and TAZ contain a C-terminal PDZ binding motif (LTWL) that allows interaction 
with several proteins involved in organ size regulation. PDZ domains typically comprise 
80-100 residues forming six β-strands, and two α-helices of differing lengths (Fig. 3). 
The binding groove is generally located between the longer α-helix and the second β-
strand [41]. Nuclear localization of YAP/TAZ is promoted by interactions with the first 
PDZ domain of the tight junction-associated proteins Zonula Occludens-1 and -2 [42, 
43]. Interactions involving PDZ binding motifs and PDZ domains, and WW domains and 
PPxY motifs, are important for Hippo pathway cross-talk with TGFβ signalling 
(YAP/TAZ interaction with Crumbs components PALS1, AMOT, PATJ and LIN7 [12]) 
and with  the Wnt pathway (TAZ interaction with Dvl [23]). 
 
Other domains within Hippo pathway proteins 
Remaining protein-protein interaction domains include those involved in self-association 
such as the dimerisation domain of α-catenin and those that lead to proteasomal 
degradation e.g. the ubiquitin-associated (UBA) domain of LATS1/2. Domains involved 
in membrane interaction and localisation include the FERM domains in Merlin and 
FRMD6, and the C2 domains in Kibra and Itch. 
 
Conclusion 
The Hippo pathway inter-connects with numerous other pathways in order to orchestrate 
organ growth or tissue regeneration, and might therefore be more appropriately termed 
the Hippo network. Substantial knowledge of Hippo network operation has rapidly 
emerged but many questions remain. In terms of protein domains, for example, how are 
the multiple possible WW, SARAH and PDZ domain interactions coordinated? What are 
the structural and functional relationships between multiple domains/motifs within and 
between proteins? How do post-translational modifications, predominantly 
phosphorylation, modulate domain structures and interactions? Detailed structural, 
biochemical, biophysical and computational analyses, including isolation or 
reconstitution of multimolecular complexes, are needed to answer questions such as 
these. In combination with cellular and organismal studies, one long-term goal of these 
molecular level studies is systems level comprehension of Hippo signalling towards 
understanding and prediction of responses to particular developmental and environmental 
cues, and towards controlled modulation for research and clinical applications.  
 
Summary 
• The Hippo pathway is a central, conserved pathway that interconnects with 
several other pathways to regulate organ growth, tissue homeostasis and 
regeneration, and stem cell self-renewal.  
• The Hippo pathway is unique in its capacity to orchestrate the multiple processes, 
from sensing to execution, necessary for organ expansion. 
• The mechanisms and effects of Hippo pathway cross-talk with other pathways 
such as Wnt and TGFβ growth factor pathways will undoubtedly turn out to be 
highly complex but are gradually being elucidated. 
• The Hippo pathway includes protein domains involved in catalysis, protein-
membrane interaction, protein-protein interaction, and protein-nucleic acid 
interaction. 
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Figure legends  
 
Figure 1: Mammalian Hippo pathway. The core Hippo pathway components within the 
orange-bordered box (MST1/2 kinases, scaffolding protein Sav1, LATS1/2 kinases and 
their cofactors MOB1A/B) target transcriptional co-activator proteins YAP and TAZ for 
phosphorylation. Phosphorylated YAP and TAZ are subsequently anchored in the 
cytoplasm by 14-3-3 proteins and the interaction is stabilised by α-catenin. Molecules 
coloured in grey antagonise the Hippo pathway by inhibiting the core kinases. 
Inactivation of the Hippo pathway allows YAP and TAZ to translocate into the nucleus 
where they contribute to the upregulation of target genes through interactions with 
transcription factors.  
 
Figure 2: Schematic representations of Hippo network proteins.  
DBD – DNA binding domain; YBD – YAP binding domain; TBD – TEAD binding 
domain; WW – domain containing two signature Trp residues; TAD – transactivation 
domain; M – vinculin-like domain; UBA – ubiquitin-associated domain; S/T KD – 
Ser/Thr kinase domain; SARAH – Sav/Rassf/Hippo domain; FERM – 4.1 
protein/ezrin/radixin/moesin domain; CTD – C-terminal domain; PH – pleckstrin 
homology domain; PDZ - post synaptic density protein/Drosophila disc large tumor 
suppressor/zonula occludens domain; SH3 – SRC homology 3 domain; P-loop – NTPase 
domain; ECD – extracellular cadherin domain; CCD – cytoplasmic cadherin domain; 
ARM – armadillo repeat; HECTc - homologous to the E6-AP carboxyl terminus; RA – 
Ras association domain. 
 
Figure 3: Structures of some Hippo pathway protein domains. A, D, F and H are NMR 
solution structures; B, C, E, G and I are crystal structures.  (A) TEAD1 DBD (PDB ID: 
2HZD); (B) TEAD1 YBD:YAP TBD complex (PDB ID: 3KYS); (C) 14-3-3σ:YAP 
phospho-peptide complex (PDB ID: 3MHR); (D) YAP WW2 domain (PDB ID: 2L4J); 
(E) S. cerevisiae MOB1 (PDB ID: 2HJN) (F) mouse Sav WW2 domain dimer (PDB ID: 
2DWV); (G) ZO1 PDZ1 domain (PDB ID: 2H3M); (H) MST1 SARAH domain (PDB 
ID: 2JO8); (I) Mst1 kinase domain (PDB ID: 3COM). 
 Table 1 Cross-talk between Hippo pathway proteins and other signalling pathways  
Pathway cross-talk Hippo pathway protein interaction 
The Hippo pathway 
inhibits Wnt/β-catenin 
signalling    
(Varelas et al. 2010) 
Direct interaction of TAZ with Dvl2 inhibits phosphorylation of 
Dvl2 by CK1δ/ε thereby preventing formation of the β-catenin 
destruction complex. This results in β-catenin nuclear localisation 
and expression of Wnt target genes. 
The Hippo pathway 
inhibits 
BMP/TGFβ  signalling 
(Alarcon et al. 2009; 
Varelas et al. 2010) 
Direct interaction of YAP with phospho-Smad1 and YAP/TAZ 
with phospho-Smad2/3 retains Smads in the nucleus and leads to 
transcription of TGFβ/Smad target genes. 
The Hippo pathway 
inhibits JAK/STAT 
signalling  
(Karpowicz et al. 2010) 
Nuclear Yki induces transcription of cytokines that promote 
JAK/STAT signalling in response to injury. 
The Hippo pathway  
inhibits Notch 
signalling 
(Reddy et al. 2010) 
Nuclear Yki inhibits the Notch ligand Delta which leads to Notch 
activation. 
Sonic hedgehog (Shh) 
signalling inhibits the 
Hippo pathway 
(Fernandez et al. 2009) 
Shh signalling up-regulates expression of YAP1 mRNA, and 
stabilises IRS1 (insulin receptor substrate 1) which acts as a 
nuclear retention factor for YAP. Shh signalling also results in 
decreased levels of phospho-LATS. 
The Hippo pathway 
promotes FoxO 
signalling  
(Choi et al. 2009) 
MST1 phosphorylates FoxO proteins leading to nuclear 
localisation and transcription of FoxO target genes. 
PI3 kinase (PI3K)/Akt 
signalling inhibits the 
Hippo pathway 
(Yuan et al. 2010) 
Akt phosphorylates MST1 (at T120), thereby preventing the kinase 
activity of MST1. 
Retinoblastoma (Rb)  
(Nicolay et al. 2011; 
Tschop et al. 2011) 
The transcription factor E2F is negatively regulated by Rb. E2F 
interacts with the Yki-Sd complex and therefore Rb inhibits E2F-
Yki-Sd mediated transcription. In humans, LATS phosphorylates 
DYRK (dual-specificity tyrosine phosphorylation-regulated 
kinases) which leads to activation of the ‘DREAM’ complex and 
inhibition of E2F.    
EGF-Receptor 
signalling   
(Zhang et al. 2009) 
YAP mediates transcription of the EGF-R ligand amphiregulin, 
leading to proliferation and migration of neighbouring cells.  
 Table 2 Binding partners of YAP and TAZ 
Binding protein Description of binding protein YAP/TAZ domain 
involved 
14-3-3 (Kanai et al. 2000; Basu 
et al. 2003) 
Dimeric proteins that sequester 
YAP/TAZ to the cytoplasm 
Phosphorylated 14-
3-3 binding motif 
AMOT (Chan et al. 2011) Angiomotin part of the Crumbs 
complex 
WW domain(s) 
ASPP1/2 (p53BP) (Espanel and 
Sudol 2001; Liu et al. 2011) 
Apoptosis-stimulating protein of p53 
protein family 
WW domain(s) 
c-Yes (Sudol et al. 1995) Tyrosine kinase SH3 binding motif 
Crb (Varelas et al. 2010) Upstream Hippo pathway complex 
protein Crumbs  
WW domain(s) and 
PDZ-binding motif 
Dvl2 (Varelas et al. 2010) Dishevelled polarity protein involved 
in Wnt signalling 
WW domain and 
PDZ binding motif 
ErbB4 (Komuro et al. 2003) Receptor tyrosine kinase that contains 
a cleavable cytoplasmic fragment 
WW domain(s) 
Ex (Badouel et al. 2009) Upstream Hippo pathway FERM-
domain protein 
WW domain(s) 
HNRNPU (Howell et al. 2004) Heterogenous nuclear ribonuclear 
protein U binds to YAP and p73 
Proline-rich region 
at N-terminus of 
YAP 
LATS1/2 (Lei et al. 2008; 
Zhang et al. 2008) 
Hippo pathway Ser/Thr kinases WW domain(s) 
NFE2 (p45) (Gavva et al. 1997) Haemopoietic transcription factor-2 WW domain(s) 
NHERF (EPB50) (Mohler et 
al. 1999; Kanai et al. 2000) 
Recruits YAP and TAZ to plasma 
membrane 
PDZ binding motif 
p73 (Strano et al. 2001; Oka 
and Sudol 2009) 
Pro-apoptotic transcription factor WW domain(s)  
PEBP2 (Yagi et al. 1999) Polyoma enhancer binding protein 2 
transcription factor 
WW domain(s) 
PPARγ  
(Hong et al. 2005) 
Adipocyte transcription factor WW domain(s) 
PRGP2 (Kulman et al. 2007) Proline-rich membrane Gla protein WW domain(s) 
Runx1/2 (Zaidi et al. 2004; 
Hong et al. 2005) 
Transcription factors with Runt DNA-
binding domain 
WW domain(s) 
Smads (Alarcon et al. 2009; 
Aragon et al. 2011) 
Transcription factors regulated by the 
TGFβ BMP signalling pathway 
WW domain(s) 
TEAD (Vassilev et al. 2001) Transcription factors TBD 
WBP1/2 (Chen and Sudol 
1995) 
WW domain-binding proteins WW domain(s) 
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